These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 6364432)

  • 1. The role of complement in immune clearance of blood cells.
    Nydegger UE; Kazatchkine MD
    Springer Semin Immunopathol; 1983; 6(4):373-98. PubMed ID: 6364432
    [No Abstract]   [Full Text] [Related]  

  • 2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins.
    Jasinski M; Pantazopoulos P; Rother RP; van Rooijen N; Song WC; Molina H; Bessler M
    Blood; 2004 Apr; 103(7):2827-34. PubMed ID: 14645002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets.
    Dixon RH; Rosse WF
    J Clin Invest; 1977 Feb; 59(2):360-8. PubMed ID: 833281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells.
    Sica M; Notaro R
    Am J Hematol; 2024 Mar; 99(3):505-507. PubMed ID: 38264841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysis of red blood cells in some haemolytic anaemias--the lytic effect of agkistrodon piscivorus venom in vitro.
    Brabec V; Kornalík F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(3):428-35. PubMed ID: 72030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
    DeZern AE; Brodsky RA
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alternative pathway of complement activation: molecular organization. Biological importance].
    Mirapeix E
    Med Clin (Barc); 1983 Dec; 81(18):817-21. PubMed ID: 6361404
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulation of the alternative pathway of complement by pH.
    Fishelson Z; Horstmann RD; Müller-Eberhard HJ
    J Immunol; 1987 May; 138(10):3392-5. PubMed ID: 2952717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the proportion of paroxysmal nocturnal hemoglobinuria (PNH) III-erythrocytes and the frequency of exacerbated hemoglobinuria in PNH.
    Shichishima T; Terasawa T; Uchida T; Maruyama Y
    Eur J Haematol; 1991 Sep; 47(3):235-6. PubMed ID: 1915809
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ; Baker PJ; Rosse WF
    J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The membrane abnormalities in paroxysmal nocturnal hemoglobinuria (PNH).
    Rosse WF; Adams JP
    Prog Clin Biol Res; 1979; 30():457-61. PubMed ID: 531036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab.
    Risitano AM; Notaro R; Luzzatto L; Hill A; Kelly R; Hillmen P
    N Engl J Med; 2010 Dec; 363(23):2270-2. PubMed ID: 21121856
    [No Abstract]   [Full Text] [Related]  

  • 14. Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease.
    Halperin JA; Nicholson-Weller A
    Complement Inflamm; 1989; 6(1):65-72. PubMed ID: 2650991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hemolytic anemia, myocardial infarction and xenotransplantation: what do they have in common?].
    Schifferli JA
    Schweiz Med Wochenschr; 1995 Nov; 125(46):2217-25. PubMed ID: 8525341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-lymphocytes escape membrane defect in paroxysmal nocturnal haemoglobinuria.
    Cooper MR; Currie MS; Rustagi PK; Logue GL
    Br J Haematol; 1983 Oct; 55(2):263-71. PubMed ID: 6604541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice.
    Sylvestre D; Clynes R; Ma M; Warren H; Carroll MC; Ravetch JV
    J Exp Med; 1996 Dec; 184(6):2385-92. PubMed ID: 8976192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.